Trust Co. of Toledo NA OH trimmed its stake in shares of Abbott Laboratories (NYSE:ABT) by 1.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 81,001 shares of the healthcare product maker’s stock after selling 1,271 shares during the period. Abbott Laboratories comprises about 1.1% of Trust Co. of Toledo NA OH’s investment portfolio, making the stock its 21st largest position. Trust Co. of Toledo NA OH’s holdings in Abbott Laboratories were worth $4,623,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Capital Research Global Investors increased its stake in Abbott Laboratories by 45.7% in the 2nd quarter. Capital Research Global Investors now owns 47,589,663 shares of the healthcare product maker’s stock valued at $2,313,334,000 after buying an additional 14,918,038 shares during the last quarter. Janus Henderson Group PLC increased its stake in Abbott Laboratories by 3,373.9% in the 2nd quarter. Janus Henderson Group PLC now owns 7,874,473 shares of the healthcare product maker’s stock valued at $382,779,000 after buying an additional 7,647,798 shares during the last quarter. Vanguard Group Inc. increased its stake in Abbott Laboratories by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 129,786,955 shares of the healthcare product maker’s stock valued at $6,308,944,000 after buying an additional 3,241,063 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Abbott Laboratories by 28.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 11,722,088 shares of the healthcare product maker’s stock valued at $569,830,000 after buying an additional 2,606,404 shares during the last quarter. Finally, Harding Loevner LP increased its stake in Abbott Laboratories by 73.5% in the 3rd quarter. Harding Loevner LP now owns 4,171,941 shares of the healthcare product maker’s stock valued at $125,189,000 after buying an additional 1,767,384 shares during the last quarter. Institutional investors and hedge funds own 72.35% of the company’s stock.

How to Become a New Pot Stock Millionaire

ABT has been the topic of several recent research reports. Zacks Investment Research lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Royal Bank of Canada reiterated a “buy” rating and issued a $65.00 price target on shares of Abbott Laboratories in a research note on Tuesday, January 9th. Evercore ISI assumed coverage on shares of Abbott Laboratories in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $64.00 price target on the stock. ValuEngine raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating in a research report on Wednesday, November 22nd. Finally, BTIG Research downgraded shares of Abbott Laboratories from a “buy” rating to a “neutral” rating in a research report on Monday, January 22nd. They noted that the move was a valuation call. Seven analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $65.47.

In related news, insider Brian J. Blaser sold 27,733 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $62.26, for a total transaction of $1,726,656.58. Following the completion of the transaction, the insider now directly owns 156,587 shares in the company, valued at approximately $9,749,106.62. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Jared Watkin sold 996 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $58.87, for a total transaction of $58,634.52. Following the transaction, the senior vice president now owns 69,511 shares of the company’s stock, valued at $4,092,112.57. The disclosure for this sale can be found here. Insiders sold a total of 124,261 shares of company stock valued at $7,559,987 over the last 90 days. Corporate insiders own 0.76% of the company’s stock.

Shares of Abbott Laboratories stock opened at $62.42 on Thursday. Abbott Laboratories has a 12 month low of $42.31 and a 12 month high of $64.60. The company has a quick ratio of 1.86, a current ratio of 2.26 and a debt-to-equity ratio of 0.87. The firm has a market cap of $109,407.83, a PE ratio of 240.09, a price-to-earnings-growth ratio of 1.86 and a beta of 1.52.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.01. Abbott Laboratories had a net margin of 1.74% and a return on equity of 13.88%. The business had revenue of $7.59 billion during the quarter, compared to analysts’ expectations of $7.38 billion. During the same quarter in the previous year, the company earned $0.65 EPS. The business’s revenue was up 42.3% on a year-over-year basis. equities analysts expect that Abbott Laboratories will post 2.86 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, May 15th. Stockholders of record on Friday, April 13th will be given a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 1.79%. The ex-dividend date is Thursday, April 12th. Abbott Laboratories’s payout ratio is presently 430.79%.

COPYRIGHT VIOLATION NOTICE: “Abbott Laboratories (ABT) Shares Sold by Trust Co. of Toledo NA OH” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.watchlistnews.com/abbott-laboratories-abt-shares-sold-by-trust-co-of-toledo-na-oh/1956078.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.